Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.73
-6.38 (-3.04%)
AAPL  265.27
+0.69 (0.26%)
AMD  195.22
-4.93 (-2.46%)
BAC  51.28
-1.78 (-3.35%)
GOOG  312.47
-2.43 (-0.77%)
META  642.64
-13.02 (-1.99%)
MSFT  385.77
-11.46 (-2.88%)
NVDA  189.99
+0.17 (0.09%)
ORCL  139.34
-8.74 (-5.90%)
TSLA  399.27
-12.55 (-3.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.